Neurocrine Biosciences Announces Two-Year Data from Phase 3 CAHtalyst Adult Study
Neurocrine Biosciences (NBIX) presented new two-year data showing sustained reductions in glucocorticoid doses for patients with classic congenital adrenal hyperplasia treated with CRENESSITY®. The results showed that around 70% of patients achieved physiologic GC dose levels, and approximately 75% transitioned off dexamethasone without compromising control.
Tickers: $NBIX
Topics: clinical trials congenital adrenal hyperplasia CRENESSITY drug development Neurocrine Biosciences